Bayer’s (BAYRY) has progressed well with its newly launched products in the last few quarters. Drugs like Eylea (Eye), Stivarga (oncology), Xarelto (anticoagulant), Xofigo (oncology) and Adempas (pulmonary hypertension) posted sales of €598 million in the first quarter and are expected to contribute around €2.8 billion in 2014. The company is looking to get these…
PRevious Few Days have been very eventful for the Biotech Stocks. Last week, earnings remained in focus with several companies reporting their second quarter results. While Amgen’s (AMGN) results remained impressive, Vertex (VRTX) posted a wider loss. Meanwhile, Regeneron (REGN) missed earnings expectations by a pretty wide margin though Eylea sales continued to impress. Among…
Regeneron Pharmaceuticals’ (REGN) second quarter 2014 adjusted earnings (including stock-based compensation expense) of $1.89 per share were well short of the Consensus Estimate of $2.33. The company had earned $1.36 per share in the year-ago quarter. Results were impacted by higher costs. Including one-time items, earnings increased 3.8% to 82 cents per share. A higher…
The outbreak of the deadly and highly infectious Ebola disease in Africa has already claimed multiple lives. According to media reports many health workers including doctors and nurses have also fallen a prey to the worst outbreak of the disease. According to the World Health Organization (WHO), the disease first surfaced in 1976. Among other…
Amgen (AMGN) reported second quarter 2014 earnings of $2.37 per share, well above the Consensus Estimate of $1.99 and the year-ago earnings of $1.88. Total revenues increased 11% to $5,180 million in the second quarter of 2014, beating the Consensus Estimate of $4,875 million. Including one-time items, second quarter earnings increased 22% to $2.01 per…
Vertex Pharmaceuticals Inc.’s (VRTX) second-quarter 2014 loss came in at 79 cents per share (including stock-based compensation expense), much wider than the loss of 21 cents reported in the year-ago quarter. Second quarter 2014 loss was also wider than the Consensus Estimate of a loss of 74 cents. Excluding the impact of stock-based compensation expense,…
